Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
7.35
-0.08 (-1.08%)
Jan 17, 2025, 4:00 PM EST - Market closed
Profound Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Profound Medical stock have an average target of 11.4, with a low estimate of 10.8 and a high estimate of 12. The average target predicts an increase of 55.10% from the current stock price of 7.35.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 16, 2024.
Analyst Ratings
The average analyst rating for PROF stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold → Strong Buy Upgrades $9 → $12 | Hold → Strong Buy | Upgrades | $9 → $12 | +63.27% | Jul 16, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +46.94% | Mar 11, 2024 |
| Stifel | Stifel | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +22.45% | Mar 8, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +73.47% | Jan 4, 2024 |
| Stifel | Stifel | Hold Initiates $11 | Hold | Initiates | $11 | +49.66% | Nov 28, 2023 |
Financial Forecast
Revenue This Year
11.35M
from 7.20M
Increased by 57.62%
Revenue Next Year
29.56M
from 11.35M
Increased by 160.54%
EPS This Year
-1.18
from -1.35
EPS Next Year
-0.92
from -1.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.9M | 42.4M | 82.1M | |||
| Avg | 11.3M | 29.6M | 56.0M | |||
| Low | 11.0M | 16.1M | 32.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 64.8% | 273.8% | 177.7% | |||
| Avg | 57.6% | 160.5% | 89.5% | |||
| Low | 52.5% | 41.6% | 9.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.02 | -0.22 | 0.22 | |||
| Avg | -1.18 | -0.92 | -0.56 | |||
| Low | -1.28 | -1.39 | -1.34 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.